Please provide your email address to receive an email when new articles are posted on . Moderate exacerbations shared similar characteristics with severe exacerbations. Lung function, limitations and ...

Posters presented at ACAAI 2023 Annual Scientific Congress examined dupilumab use in children with moderate-to-severe asthma and in the presence of elevated type 2 biomarkers. Two posters presented at ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Children with uncontrolled, moderate to severe asthma ...

Dupilumab significantly reduced the risk of exacerbations compared with placebo in children with moderate to severe asthma, regardless of exacerbation history. Dupilumab was shown to consistently ...

Credit: Thinkstock. Investigators assessed a real-world pediatric patients with asthma who used biologic therapy to identify their response to prescribed biologics and reasons for discontinuation of ...

The addition of a house dust mite (HDM) sublingual allergen immunotherapy (SLIT) tablet to maintenance medications improved time to first moderate or severe asthma exacerbation during a period of ...

“Mepolizumab and tezepelumab demonstrated the greatest reductions in asthma exacerbations vs placebo over 24 and 52 weeks, respectively.” Mepolizumab and tezepelumab were associated with the greatest ...

Adolescents with overweight or obesity and asthma had a lower risk of asthma exacerbations after starting a GLP-1 receptor ...

PHOENIX, Arizona — In a 15-month phase 4 trial, an inexpensive intervention that can be explained in a single office visit reduced severe exacerbations and improved asthma control in patient ...

Black and Latinx patients who took inhaled corticosteroids when they used reliever medications, in addition to usual care, had fewer severe asthma exacerbations, improved asthma control, improved ...

A new medication has been added to the treatment options for children with moderate-to-severe asthma. In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma ...